Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative

Company Overview - Kiniksa Pharmaceuticals, Ltd. is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases and significant unmet medical needs [1][5] - The company has a pipeline of immune-modulating assets, including ARCALYST, abiprubart, and mavrilimumab, targeting underserved cardiovascular and autoimmune conditions [1][5] Initiative Sponsorship - Kiniksa announced its sponsorship of the American Heart Association's Addressing Recurrent Pericarditis initiative, aimed at improving quality of care for recurrent pericarditis patients [5][11] - The initiative will establish a learning collaborative at fifteen healthcare sites to analyze patient identification and referral pathways, with the goal of improving outcomes and quality of life for patients [7][11] Recurrent Pericarditis Insights - Recurrent pericarditis is characterized by inflammation of the pericardium, leading to significant impacts on quality of life, frequent emergency visits, and hospitalizations [8][12] - Approximately 40,000 patients in the U.S. seek treatment for recurrent pericarditis annually, with around 14,000 experiencing two or more recurrences [8][12]